Morepen Laboratories Ltd. — Investor Presentation 2021

Jul 27, 2021

==> picture [92 x 841] intentionally omitted <==

==> picture [48 x 74] intentionally omitted <==

==> picture [159 x 38] intentionally omitted <==

Date: 27/07/2021

To,

National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288

Subject: Investors Presentation (Q1’FY22) July, 2021

Dear Sir,

Please find enclosed the Investors Presentation (Q1’FY22) July, 2021 , based on the financial performance of the Company for the quarter ended 30[th] June, 2021.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

==> picture [73 x 73] intentionally omitted <==

For Morepen Laboratories Limited

(Vipul Kumar Srivastava) Company Secretary

Encl.: As above.

Morepen Laboratories Limited

Corp. Off.: 4[th] Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi- 110 001, INDIA Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: ww.morepen.com CIN NO. L24231 HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205 Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com

MOREPEN LABORATORIES LIMTED

Q1'FY22 earnings Presentation - JULY 2021

==> picture [594 x 810] intentionally omitted <==

Disclaimer/ Confidentiality

This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.

This presentation has been prepared by the Company based on information an data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise.

The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / advice may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.

This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.

This presentation contain confidential data and information about the company historical performance and future business plan strategy and the any reader/user can not copy, circuculate or use disclose the said information or part of it to anyone without prior written permission of the Company. Any unauthorised use of the data will attract legal action against the person.

.

==> picture [142 x 35] intentionally omitted <==

C O N S O L I D A T E D

==> picture [594 x 810] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 performance
Rs. in crores
Net Revenue E B I D T A
258.97 388.31
27.90 45.43
Profit after Tax EPS (3M)
19.36 30.47 Rs. 0.43 Rs. 0.68
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
----- End of picture text -----

QUARTERLY HIGHLIGHTS

Rs. in crores

==> picture [364 x 404] intentionally omitted <==

----- Start of picture text -----

Profit before Tax
19.55 38.53
Q1'FY21 Q1'FY22
----- End of picture text -----

==> picture [359 x 81] intentionally omitted <==

==> picture [331 x 68] intentionally omitted <==

==> picture [94 x 249] intentionally omitted <==

==> picture [94 x 248] intentionally omitted <==

Morepen starts trial production of Sputnik V in India for RDIF Press Release: 6th July 2021

==> picture [477 x 176] intentionally omitted <==

Trial samples of 6 batches bein sent to Gamel a g y , Moscow f o r testin . g Can start commercial ~~-~~ roduction within 4 6 p week s sub j ect to regulator y clearances ~~.~~ Capacit y to produce upto 250 mn doses pa which can be increased to 500mn doses a. p

==> picture [387 x 600] intentionally omitted <==

==> picture [1055 x 212] intentionally omitted <==

==> picture [688 x 72] intentionally omitted <==

==> picture [422 x 567] intentionally omitted <==

CONSOLIDATED q u a r t e r l y p e r f o r m a n c e

==> picture [553 x 49] intentionally omitted <==

==> picture [635 x 252] intentionally omitted <==

==> picture [387 x 212] intentionally omitted <==

==> picture [422 x 36] intentionally omitted <==

C O N S O L I D A T E D

REVENUE GROWTH

==> picture [92 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [276 x 328] intentionally omitted <==

----- Start of picture text -----

1,250
1200
1,000
863
750
772
610
500
250
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

Rs. in crores

==> picture [625 x 426] intentionally omitted <==

----- Start of picture text -----

400
388.31
300
258.97
200
IGHEST
100
EVER
GROWTH
0
Q1'FY21 Q1'FY22
IN A QTR
----- End of picture text -----

Q1'FY22 performance

==> picture [142 x 35] intentionally omitted <==

C O N S O L I D A T E D

==> picture [1316 x 733] intentionally omitted <==

----- Start of picture text -----

BUSINESS SEGMENTS
API BUSINESS MEDIC A L DEVICES
FOR M ULA T IONS O TC ( S UB S IDI ARY)
----- End of picture text -----

==> picture [71 x 810] intentionally omitted <==

C O N S O L I D A T E D

SEGMENTS WISE GROWTH

==> picture [1411 x 564] intentionally omitted <==

----- Start of picture text -----

A P I D I A G N O S T I C S FORMULATIONS
DR.MOREPEN -OTC
200 150
40 25
189.97
134.46 39.90
150
162.05 20 23.65
100 30 21.69
30.65
15
100
20
50 10
50
46.56 10
5
0 0
0 0
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
Non-Covid Revenue Growth 172%
----- End of picture text -----*

==> picture [1439 x 810] intentionally omitted <==

----- Start of picture text -----

S T A N D A L O N E
SEGMENT WISE BREAKUP
Formulations share FY'21 q1'FY22
11%
API 9.90%
62.0% 52.1
API
52.1% %
Diagnostic Devices
36.9%
Diagnostics
10.8%
26.1% 36.9
%
revenue split Q1'FY'22
formulations
11.9% 11.0%
0.80%
----- End of picture text -----

==> picture [387 x 600] intentionally omitted <==

==> picture [1055 x 212] intentionally omitted <==

==> picture [422 x 567] intentionally omitted <==

==> picture [688 x 72] intentionally omitted <==

API BUSINESS l e a d e r s h i p t h r o u g h q u a l i t y

==> picture [553 x 48] intentionally omitted <==

==> picture [635 x 247] intentionally omitted <==

==> picture [387 x 212] intentionally omitted <==

==> picture [422 x 36] intentionally omitted <==

a p i b u s i n e s s

API REVENUE

==> picture [93 x 33] intentionally omitted <==

==> picture [127 x 33] intentionally omitted <==

==> picture [302 x 353] intentionally omitted <==

----- Start of picture text -----

750
683
500
474
413
339
250
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

==> picture [75 x 135] intentionally omitted <==

==> picture [106 x 135] intentionally omitted <==

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

200
189.97
150
162.06
100
50
0
Q1'FY21 Q1'FY22
----- End of picture text -----

==> picture [282 x 25] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 performance
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

a p i b u s i n e s s

==> picture [1412 x 733] intentionally omitted <==

----- Start of picture text -----

KEY API PRODUCTS
MONTELUK A ST
L O R A T A D I N E
^ 1 6 % ^ 4 5 %
A T OR VAS T AT IN NEW MOLECULES
^ 1 1 0 %
- 5 %
----- End of picture text -----

==> picture [387 x 494] intentionally omitted <==

==> picture [951 x 212] intentionally omitted <==

==> picture [106 x 810] intentionally omitted <==

==> picture [688 x 72] intentionally omitted <==

==> picture [318 x 600] intentionally omitted <==

POC MEDICAL DEVICES

m a r k e t l e a d e r s h i p

==> picture [387 x 318] intentionally omitted <==

==> picture [553 x 49] intentionally omitted <==

==> picture [635 x 252] intentionally omitted <==

P O C m e d i c a l d e v i c e s

POC REVENUE

Rs. in crores

==> picture [292 x 324] intentionally omitted <==

----- Start of picture text -----

300
287.35
200
168.35
139.75
100
103.35
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

==> picture [625 x 426] intentionally omitted <==

----- Start of picture text -----

150
134.46
100
50 HIGHEST
46.56
EVER
GROWTH
0 Q1'FY21 Q1'FY22 IN A QTR
----- End of picture text -----

==> picture [282 x 25] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 performance
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

==> picture [891 x 811] intentionally omitted <==

----- Start of picture text -----

^233%
g l u c o m e t e r s
^730%
n e b u l i s e r s
oxygen concentrator
----- End of picture text -----

==> picture [176 x 353] intentionally omitted <==

p o c m e d i c a l d e v i c e s

GROWTH DRIVERS

^183% B P M o n i t o r s ^2032% o x i m e t e r s

==> picture [141 x 459] intentionally omitted <==

==> picture [37 x 90] intentionally omitted <==

==> picture [283 x 89] intentionally omitted <==

==> picture [108 x 24] intentionally omitted <==

P O C m e d i c a l d e v i c e s

GLUCO METER REVENUE

==> picture [83 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [271 x 314] intentionally omitted <==

----- Start of picture text -----

200
180.46
150
119.55
100
92.92
64.81
50
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

==> picture [273 x 24] intentionally omitted <==

----- Start of picture text -----

Annual performance
----- End of picture text -----

==> picture [122 x 227] intentionally omitted <==

==> picture [96 x 214] intentionally omitted <==

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

100
84.68
75
50
25
25.44
0
Q1'FY21 Q1'FY22
----- End of picture text -----

Q1'FY22 performance

==> picture [181 x 206] intentionally omitted <==

----- Start of picture text -----

HIGHEST
EVER
GROWTH
IN A QTR
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

P O C m e d i c a l d e v i c e s

==> picture [594 x 810] intentionally omitted <==

----- Start of picture text -----

2
1.692
1.5
1
0.979
0.774
0.622
0.5
0
FY'18 FY'19 FY'20 FY'21
million meter installed
----- End of picture text -----

GLUCO METER INSTALLED

==> picture [182 x 44] intentionally omitted <==

==> picture [181 x 44] intentionally omitted <==

==> picture [684 x 224] intentionally omitted <==

----- Start of picture text -----

5.65 MILLION 700 MILLION
m e t e r s i n s t a l l e d s t r i p s s o l d s o f a r
q1'Fy21 0 . 62 MILLION q1'Fy22 86 MILLION
----- End of picture text -----

==> picture [137 x 148] intentionally omitted <==

==> picture [67 x 103] intentionally omitted <==

P O C m e d i c a l d e v i c e s

BP MONITOR REVENUE

==> picture [93 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [281 x 340] intentionally omitted <==

----- Start of picture text -----

75
63.02
50
29.06
25
26.50
21.76
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

==> picture [142 x 35] intentionally omitted <==

==> picture [78 x 230] intentionally omitted <==

==> picture [89 x 230] intentionally omitted <==

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

25
20
20.76
15
10
7.33
5
0
Q1'FY21 Q1'FY22
----- End of picture text -----

==> picture [282 x 25] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 performance
----- End of picture text -----

==> picture [181 x 206] intentionally omitted <==

----- Start of picture text -----

HIGHEST
EVER
GROWTH
IN A QTR
----- End of picture text -----

P O C m e d i c a l d e v i c e s

OTHER PRODUCTS

==> picture [82 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [278 x 341] intentionally omitted <==

----- Start of picture text -----

50
44.87
43.89
40
37.78
30
28.46
20
10
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

==> picture [142 x 35] intentionally omitted <==

==> picture [20 x 73] intentionally omitted <==

==> picture [119 x 207] intentionally omitted <==

==> picture [56 x 122] intentionally omitted <==

==> picture [20 x 74] intentionally omitted <==

==> picture [20 x 49] intentionally omitted <==

==> picture [49 x 90] intentionally omitted <==

==> picture [50 x 77] intentionally omitted <==

==> picture [50 x 49] intentionally omitted <==

Rs. in crores

==> picture [426 x 480] intentionally omitted <==

----- Start of picture text -----

30
29.01
20
13.79
10
0
Q1'FY21 Q1'FY22
Q1'FY22 performance
----- End of picture text -----

==> picture [387 x 600] intentionally omitted <==

==> picture [1055 x 212] intentionally omitted <==

==> picture [688 x 72] intentionally omitted <==

==> picture [422 x 567] intentionally omitted <==

FORMULATIONS b r a n d e D f o r m u l a t i o n s i n i n d i a

==> picture [553 x 49] intentionally omitted <==

==> picture [635 x 252] intentionally omitted <==

==> picture [387 x 212] intentionally omitted <==

==> picture [422 x 36] intentionally omitted <==

F O R M U L A T I O N S

FORMULATIONS REVENUE

==> picture [63 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [288 x 342] intentionally omitted <==

----- Start of picture text -----

200
150
153.17
137.57
131.35
110.51
100
50
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

40
39.90
30
30.65
20
10
0
Q1'FY21 Q1'FY22
----- End of picture text -----

Q1'FY22 performance

==> picture [142 x 35] intentionally omitted <==

F O R M U L A T I O N S

GROWTH DRIVERS

==> picture [1258 x 579] intentionally omitted <==

----- Start of picture text -----

^179% ^91%
a n t i b i o t i c s v i t a m i n s
^55% ^201%
g a s t r o o t h e r s
----- End of picture text -----

==> picture [36 x 810] intentionally omitted <==

==> picture [142 x 35] intentionally omitted <==

==> picture [1440 x 810] intentionally omitted <==

----- Start of picture text -----

O T C & n u t r i t i o n
----- End of picture text -----

==> picture [219 x 70] intentionally omitted <==

GROSS REVENUE

==> picture [95 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [279 x 328] intentionally omitted <==

----- Start of picture text -----

100
85.55
75
64.63
50 54.38
48.89
25
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Annual performance

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

25
22.93
20
15
10
8.43
5
0
Q1'FY21 Q1'FY22
----- End of picture text -----

Q1'FY22 performance*

==> picture [142 x 35] intentionally omitted <==

*Non-Covid Revenue 172% Growth;Total 9%

==> picture [142 x 35] intentionally omitted <==

==> picture [1440 x 810] intentionally omitted <==

----- Start of picture text -----

GROWTH DRIVERS
^259% ^273%
O T C p r o d u c t s g r o o m i n g
^85% 110%
g e n e r a l h e a l t h 0 n l i n e S a l e s
----- End of picture text -----

==> picture [594 x 810] intentionally omitted <==

----- Start of picture text -----

Covid Range
3.1%
Healthcare
33.6%
OTC
46.5%
Grooming
16.8%
business segments q1'FY22
----- End of picture text -----

==> picture [219 x 70] intentionally omitted <==

BUSINESS SEGMENTS

on line sales

==> picture [532 x 337] intentionally omitted <==

----- Start of picture text -----

11% 33%
grooming
OTC
----- End of picture text -----

==> picture [219 x 70] intentionally omitted <==

NEW ONLINE LAUNCHES

==> picture [98 x 64] intentionally omitted <==

==> picture [125 x 143] intentionally omitted <==

==> picture [90 x 122] intentionally omitted <==

==> picture [56 x 70] intentionally omitted <==

==> picture [104 x 176] intentionally omitted <==

==> picture [142 x 141] intentionally omitted <==

==> picture [31 x 32] intentionally omitted <==

==> picture [95 x 137] intentionally omitted <==

==> picture [142 x 117] intentionally omitted <==

==> picture [140 x 68] intentionally omitted <==

==> picture [96 x 45] intentionally omitted <==

pcos powder

collagen

iron & ZInc sexual wellness Garcinia

immune tea

muscle food

==> picture [97 x 191] intentionally omitted <==

==> picture [54 x 174] intentionally omitted <==

==> picture [94 x 107] intentionally omitted <==

==> picture [87 x 165] intentionally omitted <==

==> picture [92 x 136] intentionally omitted <==

==> picture [90 x 144] intentionally omitted <==

==> picture [85 x 128] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==

==> picture [1052 x 43] intentionally omitted <==

----- Start of picture text -----

vitamins COQ-10 Giloy+Tulsi omega-3 stress & sleep slim shake
Cod Liver Oil Amla juice
----- End of picture text -----

==> picture [741 x 24] intentionally omitted <==

----- Start of picture text -----

exclusive online range launched at www.health.drmorepen.com
----- End of picture text -----

==> picture [124 x 127] intentionally omitted <==

honey

==> picture [75 x 198] intentionally omitted <==

general health

==> picture [142 x 35] intentionally omitted <==

==> picture [219 x 70] intentionally omitted <==

an established national household brand with extensive reach and trust

==> picture [95 x 33] intentionally omitted <==

==> picture [128 x 33] intentionally omitted <==

==> picture [573 x 428] intentionally omitted <==

----- Start of picture text -----

600
504.26
400
370.53 Rx
347.31 OTC
12.3%
20.4%
262,76
200
0
FY'18 FY'19 FY'20 FY'21
Devices
Annual performance
67.3%
FY'21
----- End of picture text -----

BRAND PORTFOLIO

Rs. in crores

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

200
195.85
150
100
91.29
50
0
Q1'FY21 Q1'FY22
----- End of picture text -----

==> picture [282 x 25] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 performance
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

==> picture [142 x 35] intentionally omitted <==

c o n s o l i d a t e d

==> picture [430 x 94] intentionally omitted <==

----- Start of picture text -----

increasing investment in R&D
focus on $40 Billion generic market opening up
new initiatives including bio-similars, enzymes
----- End of picture text -----

R&D SPEND

Rs. in crores

==> picture [522 x 442] intentionally omitted <==

----- Start of picture text -----

Devices
2.9%
ANDA
18.7%
API
78.4%
segment wise spend
246 people
----- End of picture text -----*

==> picture [426 x 426] intentionally omitted <==

----- Start of picture text -----

6
5.62
4
2.65
2
0
Q1'FY21 Q1'FY22
----- End of picture text -----

==> picture [186 x 25] intentionally omitted <==

----- Start of picture text -----

Q1'FY22 SPEND
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

*Includes R&D/ARD/QC team

==> picture [387 x 529] intentionally omitted <==

==> picture [986 x 212] intentionally omitted <==

==> picture [71 x 810] intentionally omitted <==

==> picture [688 x 71] intentionally omitted <==

==> picture [353 x 566] intentionally omitted <==

FINANCIAL h i g h l i g h t s & r a t i o s

==> picture [738 x 282] intentionally omitted <==

==> picture [282 x 252] intentionally omitted <==

==> picture [353 x 36] intentionally omitted <==

C O N S O L I D A T E D

REVENUE HIGHLIGHTS

Net Revenue

Expenditure

ebitda

interest

cash profit

==> picture [24 x 32] intentionally omitted <==

==> picture [457 x 208] intentionally omitted <==

----- Start of picture text -----

400 400
388.31
300 300
258.97
200 200
231.07
100 100
0 0
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
342.88
----- End of picture text -----

==> picture [833 x 407] intentionally omitted <==

----- Start of picture text -----

50
0.3 50
40 0.29
45.43
40
45.22
0.2
30
0.21 30
20 27.90 27.62
20
0.1
10
10
0 0 0
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
----- End of picture text -----

C O N S O L I D A T E D

PROFITABILITY RATIOS

==> picture [1440 x 582] intentionally omitted <==

----- Start of picture text -----

Q1' FY'21 q1'FY22 change
0.90%
EBIDTA
10.8% 11.7%
profit before tax
2.37%
7.55% 9.92%
profit after tax
7.84% 7.96%
0.12%
----- End of picture text -----

C O N S O L I D A T E D

PROFITABILITY HIGHLIGHTS

PROFIT BEFORE TAX

PROVISION FOR TAX

PROFIT AFTER TAX

EPS(RS.)

==> picture [19 x 32] intentionally omitted <==

==> picture [1440 x 382] intentionally omitted <==

----- Start of picture text -----

40
40 8 0.75
38.53
8.06 0.68
30
30 6
30.47 0.5
20 4 20
0.43
19.36
0.25
10 10
2
19.55
0.19
0 0 0
0
Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22 Q1'FY21 Q1'FY22
Q1'FY21 Q1'FY22
Diluted EPS- Rs. 0.59
----- End of picture text -----*

Take Care

t h a n k y o u